|
Broad Clinical Labs
exome sequencing wes data ![]() Exome Sequencing Wes Data, supplied by Broad Clinical Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/exome sequencing wes data/product/Broad Clinical Labs Average 95 stars, based on 1 article reviews
exome sequencing wes data - by Bioz Stars,
2026-06
95/100 stars
|
Buy from Supplier |
|
Blueprint Genetics
whole exome sequencing wes data ![]() Whole Exome Sequencing Wes Data, supplied by Blueprint Genetics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/whole exome sequencing wes data/product/Blueprint Genetics Average 86 stars, based on 1 article reviews
whole exome sequencing wes data - by Bioz Stars,
2026-06
86/100 stars
|
Buy from Supplier |
|
Caris Life Sciences
wes data ![]() Wes Data, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/wes data/product/Caris Life Sciences Average 86 stars, based on 1 article reviews
wes data - by Bioz Stars,
2026-06
86/100 stars
|
Buy from Supplier |
|
Biotechnology Information
normal wes data ![]() Normal Wes Data, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/normal wes data/product/Biotechnology Information Average 90 stars, based on 1 article reviews
normal wes data - by Bioz Stars,
2026-06
90/100 stars
|
Buy from Supplier |
|
Mendeley Ltd
nccs npc plink processed germline wes data ![]() Nccs Npc Plink Processed Germline Wes Data, supplied by Mendeley Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/nccs npc plink processed germline wes data/product/Mendeley Ltd Average 90 stars, based on 1 article reviews
nccs npc plink processed germline wes data - by Bioz Stars,
2026-06
90/100 stars
|
Buy from Supplier |
|
Mendeley Ltd
nccs npc processed somatic wes data ![]() Nccs Npc Processed Somatic Wes Data, supplied by Mendeley Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/nccs npc processed somatic wes data/product/Mendeley Ltd Average 90 stars, based on 1 article reviews
nccs npc processed somatic wes data - by Bioz Stars,
2026-06
90/100 stars
|
Buy from Supplier |
|
Federation of European Neuroscience Societies
whole exome sequence (wes) data ![]() Whole Exome Sequence (Wes) Data, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/whole exome sequence (wes) data/product/Federation of European Neuroscience Societies Average 90 stars, based on 1 article reviews
whole exome sequence (wes) data - by Bioz Stars,
2026-06
90/100 stars
|
Buy from Supplier |
|
BioSino Inc
wes/wgs/targeted sequencing data ![]() Wes/Wgs/Targeted Sequencing Data, supplied by BioSino Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/wes/wgs/targeted sequencing data/product/BioSino Inc Average 90 stars, based on 1 article reviews
wes/wgs/targeted sequencing data - by Bioz Stars,
2026-06
90/100 stars
|
Buy from Supplier |
|
Illumina Inc
wes data ![]() Wes Data, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/wes data/product/Illumina Inc Average 90 stars, based on 1 article reviews
wes data - by Bioz Stars,
2026-06
90/100 stars
|
Buy from Supplier |
Journal: Cell Genomics
Article Title: Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA
doi: 10.1016/j.xgen.2025.100987
Figure Lengend Snippet: Study design for patient cohorts and genomic analyses (A) Initial study criteria with study design based on sample availability and treatment timing. After whole-exome sequencing, PhylogicNDT and SignatureAnalyzer were used to identify clones and compare mutational signatures, respectively. Functional mutations were characterized based on existing evidence previously published or annotated in genomic databases, such as COSMIC, ClinVar, and OncoKB. (B) Signaling pathway landscape for paired-cohort participants ( n = 26) organized by time on tyrosine kinase treatment (days by sampled TKI) and acquired ( n = 8) or intrinsic ( n = 18) resistance. Known mechanisms in ERBB2 and PIK3CA are highlighted. Signaling pathways are depicted in decreasing frequency per number of mutations for the entire cohort of paired participants. Arrows indicate the subclonal trajectory as either growing, stable, or shrinking. The TP53 and ESR1+ regulator pathways were significantly mutated ( q < 0.05; MutSig, Fisher’s method). Stacked bar charts indicate relative contributions of mutational signatures identified by SignatureAnalyzer to the mutational spectrum of each participant. (C) Pathway-level comparison of mutation frequency between four cohorts: intrinsic ( n = 18), acquired ( n = 8), pre-TKI ( n = 55), and post-TKI ( n = 30). Pathways were included if they possessed at least one mutation. There were no significant differences in pathway-level mutation frequency between cohorts (Fisher’s exact test).
Article Snippet: The remainder of our genomic analysis relied on whole
Techniques: Sequencing, Clone Assay, Functional Assay, Protein-Protein interactions, Comparison, Mutagenesis
Journal: Cell Reports Medicine
Article Title: Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes
doi: 10.1016/j.xcrm.2025.102143
Figure Lengend Snippet: Clinical characteristics and germline variants associated with NPC subtypes ( n = 303 [L], 201 [A], 246 [D], and 244 [AD]) (A) Representative MRI scans of each NPC subtype (red, bulky tumor; blue, small tumor). (B) CONSORT diagram of patient selection for the NCCS cohort. (C) Association of NPC subtypes with OS and DFS. (D) Manhattan plot showing p values of germline variants associated with L, A, D, or AD subtype relative to healthy controls. Points above dashed line ( p = 8.9 × 10 −7 ) are significant variants post-Bonferroni adjustment. (E) Variants significantly associated with NPC subtypes identified in both the comparison against healthy controls and the comparison against all controls. (F and G) Tumor expression of FADS1 and DFS in A-subtype patients with CC vs. TC genotype of rs72643557 , respectively. The boxplots represent the IQR, with the horizontal line indicating the median. Mann-Whitney U test and log-rank test was used to compare between CC vs. TC in (F) and (G), respectively. Abbreviations: NPC, nasopharyngeal carcinoma; CONSORT, Consolidated Standards of Reporting Trials; QC, quality control; OS, overall survival; DFS, disease-free survival; L, limited; A, ascending; D, descending; AD, ascending-descending.
Article Snippet:
Techniques: Selection, Comparison, Expressing, MANN-WHITNEY, Control
Journal: Cell Reports Medicine
Article Title: Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes
doi: 10.1016/j.xcrm.2025.102143
Figure Lengend Snippet: Analysis of TIME in NPC subtypes using whole slide imaging ( n = 39 [L], 35 [A], 33 [D], and 48 [AD]) (A) Workflow of spatial analyses leading to immune classification based on spatial distribution and density of immune-rich tiles within the WSI of the tumor. (B) Proportion of immune-rich tiles in WSIs for the four subtypes. (C) Mean tumor-immune tile distances in WSIs for the four subtypes. (D) Distribution of the three immune classes in WSIs for the four subtypes. (E) Association of immune classes with DFS for both NCCS and JXCH cohorts. No hazard ratio was computed for JXCH cohort due to absence of DFS events in the immune-dense class. Log-rank test was used to compare between immune classes. The boxplots represent the IQR, with the horizontal line indicating the median. Mann-Whitney U test was used to compare between NPC subtypes unless otherwise indicated. Abbreviations: WSIs, whole-slide images; DFS, disease-free survival.
Article Snippet:
Techniques: Imaging, MANN-WHITNEY
Journal: Cell Reports Medicine
Article Title: Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes
doi: 10.1016/j.xcrm.2025.102143
Figure Lengend Snippet: Clinical characteristics and germline variants associated with NPC subtypes ( n = 303 [L], 201 [A], 246 [D], and 244 [AD]) (A) Representative MRI scans of each NPC subtype (red, bulky tumor; blue, small tumor). (B) CONSORT diagram of patient selection for the NCCS cohort. (C) Association of NPC subtypes with OS and DFS. (D) Manhattan plot showing p values of germline variants associated with L, A, D, or AD subtype relative to healthy controls. Points above dashed line ( p = 8.9 × 10 −7 ) are significant variants post-Bonferroni adjustment. (E) Variants significantly associated with NPC subtypes identified in both the comparison against healthy controls and the comparison against all controls. (F and G) Tumor expression of FADS1 and DFS in A-subtype patients with CC vs. TC genotype of rs72643557 , respectively. The boxplots represent the IQR, with the horizontal line indicating the median. Mann-Whitney U test and log-rank test was used to compare between CC vs. TC in (F) and (G), respectively. Abbreviations: NPC, nasopharyngeal carcinoma; CONSORT, Consolidated Standards of Reporting Trials; QC, quality control; OS, overall survival; DFS, disease-free survival; L, limited; A, ascending; D, descending; AD, ascending-descending.
Article Snippet:
Techniques: Selection, Comparison, Expressing, MANN-WHITNEY, Control
Journal: Cell Reports Medicine
Article Title: Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes
doi: 10.1016/j.xcrm.2025.102143
Figure Lengend Snippet: Analysis of TIME in NPC subtypes using whole slide imaging ( n = 39 [L], 35 [A], 33 [D], and 48 [AD]) (A) Workflow of spatial analyses leading to immune classification based on spatial distribution and density of immune-rich tiles within the WSI of the tumor. (B) Proportion of immune-rich tiles in WSIs for the four subtypes. (C) Mean tumor-immune tile distances in WSIs for the four subtypes. (D) Distribution of the three immune classes in WSIs for the four subtypes. (E) Association of immune classes with DFS for both NCCS and JXCH cohorts. No hazard ratio was computed for JXCH cohort due to absence of DFS events in the immune-dense class. Log-rank test was used to compare between immune classes. The boxplots represent the IQR, with the horizontal line indicating the median. Mann-Whitney U test was used to compare between NPC subtypes unless otherwise indicated. Abbreviations: WSIs, whole-slide images; DFS, disease-free survival.
Article Snippet:
Techniques: Imaging, MANN-WHITNEY